Aurinia Pharmaceuticals Inc. (AUPH)

NASDAQ: AUPH · IEX Real-Time Price · USD
4.88
0.00 (0.00%)
At close: Nov 25, 2022 1:00 PM
4.94
+0.06 (1.23%)
After-hours: Nov 25, 2022 4:40 PM EST
Market Cap 692.08M
Revenue (ttm) 129.00M
Net Income (ttm) -115.46M
Shares Out 141.86M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 866,513
Open 4.92
Previous Close 4.88
Day's Range 4.82 - 4.99
52-Week Range 4.49 - 24.45
Beta 0.92
Analysts Buy
Price Target 21.74 (+345.5%)
Earnings Date Nov 3, 2022

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada. [Read more]

Industry Biotechnology
IPO Date Jan 26, 1999
CEO Peter Greenleaf
Employees 300
Stock Exchange NASDAQ
Ticker Symbol AUPH
Full Company Profile

Financial Performance

In 2021, AUPH's revenue was $45.61 million, a decrease of -9.00% compared to the previous year's $50.12 million. Losses were -$180.97 million, 76.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price forecast is 21.74, which is an increase of 345.49% from the latest price.

Price Target
$21.74
(345.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Aurinia Pharmaceuticals (AUPH) Stock Down 30%?

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH ) stock are down 30% today after the company reported its latest financial results and lowered its forward guidance. AUPH stock is one of the top trending...

3 weeks ago - InvestorPlace

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of 66.67% and 46.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results

VICTORIA, British Columbia--(BUSINESS WIRE)--AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS

3 weeks ago - Business Wire

Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quarter...

4 weeks ago - Business Wire

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022

4 weeks ago - Business Wire

Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th...

1 month ago - Zacks Investment Research

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1 month ago - Business Wire

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the traject...

2 months ago - Business Wire

Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

2 months ago - Zacks Investment Research

Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the traject...

2 months ago - Business Wire

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

Investors embraced the biotech's second-quarter results.

3 months ago - The Motley Fool

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -13.64% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results

3 months ago - Business Wire

Why Aurinia Pharmaceuticals Stock Is Sliding Today

An analyst downgraded the stock.

3 months ago - The Motley Fool

Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review

VICTORIA, British Columbia and ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Pa...

3 months ago - Business Wire

Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational resu...

4 months ago - Business Wire

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nep...

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course ...

4 months ago - Business Wire

Why Aurinia Pharmaceuticals Stock Is In Retreat Today

Investors are none too pleased with the company's recent slew of hires.

4 months ago - The Motley Fool

Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that ...

4 months ago - Business Wire

Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last?

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

4 months ago - Zacks Investment Research

Why Aurinia Pharmaceuticals Stock Perked Up Today

Another buyout rumor is fueling the company's northward move today.

4 months ago - The Motley Fool

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $250,000 to C...

Los Angeles, California--(Newsfile Corp. - June 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aurinia Pharmaceutical...

5 months ago - Newsfile Corp

AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Beha...

NEW YORK , June 14, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) alleging that ...

5 months ago - PRNewsWire

Aurinia Pharmaceuticals Inc. Class Action: Levi & Korsinsky Reminds Aurinia Pharmaceuticals Inc. Investors of the Pen...

New York, New York--(Newsfile Corp. - June 13, 2022) - Levi & Korsinsky, LLP notifies investors in Aurinia Pharmaceuticals Inc. ("Aurinia Pharmaceuticals Inc." or the "Company") (NASDAQ: AUPH) of a clas...

5 months ago - Newsfile Corp

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 t...

Los Angeles, California--(Newsfile Corp. - June 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aurinia Pharmaceutical...

5 months ago - Newsfile Corp